Genetically modified cells and their use in the prophylaxis or therapy of disor ders

摘要

Cells (A) for use in gene therapy are produced by: (a) isolating mononuclear, non-adherent cells (B) from blood or cell-containing body fluids; (b) culturing (B) in a medium containing gangliosides, phospholipids, glycolipids and/ or growth factors for endothelial cells (EC), including those factors that regulate differentiation, survival, migration and/or vascularisation; (c) optionally immortalising the cells of (a) or (b) by: (i) transformation with, or activation of, an oncogene; or (ii) inactivation of a suppressor gene; and (d) optionally treating cells of (a)-(c) with a nucleic acid construct (C) for gene therapy that includes an effector gene which, by choice of suitable promoter systems, can be activated in a cell-, cell cycle- or virus-specific manner and/or by hypoxia.